Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
Various approaches of T-cell-based cancer immunotherapy are currently under investigation, among these are BiTE® (bispecific T-cell engager) antibody constructs, which have a unique design and mechanism of action. They are constructed by genetically linking onto a single polypeptide chain the minima...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
13 May 2015
|
| In: |
Expert opinion on biological therapy
Year: 2015, Jahrgang: 15, Heft: 8, Pages: 1093-1099 |
| ISSN: | 1744-7682 |
| DOI: | 10.1517/14712598.2015.1041373 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1517/14712598.2015.1041373 Verlag, Volltext: https://doi.org/10.1517/14712598.2015.1041373 
|
| Verfasserangaben: | Julia Stieglmaier, Jonathan Benjamin and Dirk Nagorsen |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1585967335 | ||
| 003 | DE-627 | ||
| 005 | 20230427034155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190107s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1517/14712598.2015.1041373 |2 doi | |
| 035 | |a (DE-627)1585967335 | ||
| 035 | |a (DE-576)515967335 | ||
| 035 | |a (DE-599)BSZ515967335 | ||
| 035 | |a (OCoLC)1341031239 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Stieglmaier, Julia |d 1979- |e VerfasserIn |0 (DE-588)13307756X |0 (DE-627)533326311 |0 (DE-576)299607259 |4 aut | |
| 245 | 1 | 0 | |a Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer |c Julia Stieglmaier, Jonathan Benjamin and Dirk Nagorsen |
| 264 | 1 | |c 13 May 2015 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.01.2019 | ||
| 520 | |a Various approaches of T-cell-based cancer immunotherapy are currently under investigation, among these are BiTE® (bispecific T-cell engager) antibody constructs, which have a unique design and mechanism of action. They are constructed by genetically linking onto a single polypeptide chain the minimal binding domains of monoclonal antibodies for tumor-associated surface antigens and for the T-cell receptor-associated molecule CD3. Concurrent engagement of the target cell antigen and CD3 leads to activation of polyclonal cytotoxic T-cells, resulting in target cell lysis. Blinatumomab, a BiTE targeting CD19, is being investigated in a broad range of B-cell malignancies and has recently been approved in the USA by the US FDA for Philadelphia chromosome-negative relapsed/refractory B-acute lymphoblastic leukemia under the trade name BLINCYTO™. The BiTE platform is one of the clinically most advanced T-cell immunotherapy options. | ||
| 650 | 4 | |a bispecific antibody | |
| 650 | 4 | |a BiTE® | |
| 650 | 4 | |a blinatumomab | |
| 650 | 4 | |a cancer immunotherapy | |
| 650 | 4 | |a T-cells | |
| 700 | 1 | |a Benjamin, Jonathan |e VerfasserIn |0 (DE-588)1174849991 |0 (DE-627)1045732559 |0 (DE-576)515967459 |4 aut | |
| 700 | 1 | |a Nagorsen, Dirk |d 1974- |e VerfasserIn |0 (DE-588)12152471X |0 (DE-627)081364245 |0 (DE-576)183363094 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on biological therapy |d Abingdon : Taylor & Francis Group, 2001 |g 15(2015), 8, Seite 1093-1099 |h Online-Ressource |w (DE-627)355985446 |w (DE-600)2091082-4 |w (DE-576)302969578 |x 1744-7682 |7 nnas |a Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer |
| 773 | 1 | 8 | |g volume:15 |g year:2015 |g number:8 |g pages:1093-1099 |g extent:7 |a Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1517/14712598.2015.1041373 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1517/14712598.2015.1041373 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190107 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 12152471X |a Nagorsen, Dirk |m 12152471X:Nagorsen, Dirk |d 60000 |e 60000PN12152471X |k 0/60000/ |p 3 |y j | ||
| 999 | |a KXP-PPN1585967335 |e 3039200887 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Julia Stieglmaier, Jonathan Benjamin and Dirk Nagorsen"]},"id":{"eki":["1585967335"],"doi":["10.1517/14712598.2015.1041373"]},"origin":[{"dateIssuedDisp":"13 May 2015","dateIssuedKey":"2015"}],"relHost":[{"pubHistory":["1.2001 -"],"part":{"issue":"8","pages":"1093-1099","year":"2015","extent":"7","volume":"15","text":"15(2015), 8, Seite 1093-1099"},"note":["Gesehen am 08.09.15"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancerExpert opinion on biological therapy","recId":"355985446","language":["eng"],"title":[{"title":"Expert opinion on biological therapy","title_sort":"Expert opinion on biological therapy"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2001-","publisher":"Taylor & Francis Group ; Ashley ; Informa Healthcare","dateIssuedKey":"2001","publisherPlace":"Abingdon ; London ; London"}],"id":{"issn":["1744-7682"],"zdb":["2091082-4"],"eki":["355985446"]}}],"physDesc":[{"extent":"7 S."}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Stieglmaier, Julia","given":"Julia","family":"Stieglmaier"},{"role":"aut","display":"Benjamin, Jonathan","roleDisplay":"VerfasserIn","given":"Jonathan","family":"Benjamin"},{"family":"Nagorsen","given":"Dirk","roleDisplay":"VerfasserIn","display":"Nagorsen, Dirk","role":"aut"}],"title":[{"title_sort":"Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer","title":"Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer"}],"recId":"1585967335","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 07.01.2019"]} | ||
| SRT | |a STIEGLMAIEUTILIZINGT1320 | ||